Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6923708 | 0.76 | KDM4E (0.48) | KDM4EMEN1KMT2A | |
| SCHEMBL1141198 | 0.75 | HCRTR1 (0.37) | KDM4EALDH1A1HPGDMEN1KMT2A | |
| SCHEMBL20801391 | 0.71 | SLC2A1 (0.48) | ALDH1A1ACHE | |
| SCHEMBL1141261 | 0.71 | OPRD1 (0.42) | NPC1RAB9AMEN1KMT2ATSHR | |
| SCHEMBL31037653 | 0.69 | PRMT5 (0.47) | ALDH1A1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL21632108 | 0.69 | BCHE (0.47) | KDM4EALDH1A1HPGDSMN1; SMN2RAB9A | |
| SCHEMBL28872741 | 0.68 | POLB (0.46) | SMN1; SMN2KMT2AACHE | |
| SCHEMBL17675656 | 0.67 | ACHE (0.52) | KDM4EALDH1A1RAB9AACHE | |
| SCHEMBL211489 | 0.67 | POLB (0.51) | KDM4EALDH1A1HPGDCYP2C19KMT2A | |
| SCHEMBL24732593 | 0.67 | ACHE (0.45) | MAPTACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180222906-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2018-08-09 | — | — | US | disclosed |
| US-9938275-B2 | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-04-10 | — | — | US | disclosed |
| US-20170129891-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES CO (US) | 2017-05-11 | — | — | US | disclosed |
| US-9550773-B2 | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-01-24 | — | — | US | disclosed |
| US-20150218162-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2015-08-06 | — | — | US | disclosed |
| US-9006264-B2 | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2015-04-14 | — | — | US | disclosed |
| US-20140011777-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-01-09 | — | — | US | disclosed |
| US-8541438-B2 | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-09-24 | — | — | US | disclosed |
| US-20110092477-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2011-04-21 | — | — | US | disclosed |
| US-7884207-B2 | such as 4-[(4-Amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-pyran-4-ol, used as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-02-08 | — | — | US | disclosed |
| US-20070287724-A1 | Substituted Imidazoquinolines, Imidazopyridines, and Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222906-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | IL2, IFNG, IL4 | KDM4E 3854/4885ALDH1A1 2159/4885HPGD 181/4885 |
| US-20140011777-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | IL2, IFNG, IL4 | KDM4E 3854/4885ALDH1A1 2159/4885HPGD 181/4885 |
| US-20070287724-A1 | Substituted Imidazoquinolines, Imidazopyridines, and Imidazonaphthyridines | IL2, IFNG, IL4 | KDM4E 3700/4885ALDH1A1 2253/4885HPGD 220/4885 |
| US-20150218162-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | IL2, IFNG, IL4 | KDM4E 3854/4885ALDH1A1 2159/4885HPGD 181/4885 |
| US-20110092477-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | IL2, IFNG, IL4 | KDM4E 3854/4885ALDH1A1 2159/4885HPGD 181/4885 |
| US-20170129891-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | IL2, IFNG, IL4 | KDM4E 3854/4885ALDH1A1 2159/4885HPGD 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.